Castle Biosciences Inc. Common Stock (CSTL)
Stock · NASDAQ · Health Care
$31.95as of 10/16/2026
Price chart
Active signals
CSTL Signal Track Record
How signals performed across all stocks →What CSTL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | -0.1% | 50% | September 15, 2026 |
| Bollinger Band Breakout | 23 | -1.4% | 48% | September 17, 2026 |
| Bollinger Band BreakdownActive now | 23 | +6.2% | 70% | May 7, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +2.6% | 60% | August 18, 2026 |
| Any 20-session window (baseline) | +1.9% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invas…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 1,002
- Website
- castlebiosciences.com/
Fundamentals
- 1-day range
- $31.93$34.15
- Market cap
- $930.84M
- P/E (trailing)
- —
- P/E (forward)
- -35.10
- EPS (trailing)
- $-0.65
- Dividend yield
- —
- Beta
- 0.99
- Avg. volume
- 403.9K
How Castle Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Castle Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CSTLCastle Biosciences Inc. Common Stock$31.96▼ 5.44%Market cap $930.84MP/E —$17.72$44.28
- LMRILumexa Imaging Holdings Inc. Common Stock$10.78▲ 0.00%Market cap $1.10BP/E —$6.45$19.45
- FRNMFreenome Inc. Common stock$11.75▼ 4.35%Market cap $1.17BP/E —$9.97$17.5
- TRUPTrupanion Inc. Common Stock$28.12▲ 0.93%Market cap $1.23BP/E 53.48$21.16$46.98
- FLGTFulgent Genetics Inc. Common Stock$19.81▼ 7.17%Market cap $510.41MP/E —$13.46$31.04
- PSNLPersonalis Inc. Common Stock$15.65▼ 1.76%Market cap $1.39BP/E —$4.96$18.89
- TLSITriSalus Life Sciences Inc. Common Stock$3.63▼ 6.92%Market cap $299.10MP/E —$2.2$7.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CSTL Castle Biosciences Inc. Common Stock | $930.84M | — | $31.96 | ▼ 5.44% | $17.72$44.28 |
| LMRI Lumexa Imaging Holdings Inc. Common Stock | $1.10B | — | $10.78 | ▲ 0.00% | $6.45$19.45 |
| FRNM Freenome Inc. Common stock | $1.17B | — | $11.75 | ▼ 4.35% | $9.97$17.5 |
| TRUP Trupanion Inc. Common Stock | $1.23B | 53.48 | $28.12 | ▲ 0.93% | $21.16$46.98 |
| FLGT Fulgent Genetics Inc. Common Stock | $510.41M | — | $19.81 | ▼ 7.17% | $13.46$31.04 |
| PSNL Personalis Inc. Common Stock | $1.39B | — | $15.65 | ▼ 1.76% | $4.96$18.89 |
| TLSI TriSalus Life Sciences Inc. Common Stock | $299.10M | — | $3.63 | ▼ 6.92% | $2.2$7.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Tobin W. Juvenal · August 25, 2026 · Sale9.1K @ $35.04
- Kristen M. Oelschlager · August 25, 2026 · Sale5.2K @ $34.64
- Kristen M. Oelschlager · August 25, 2026 · Sale7.2K @ $34.26
- Kristen M. Oelschlager · August 24, 2026 · Sale12.2K @ $33.69
- Derek J. Maetzold · August 5, 2026 · Option Exercise2.5K @ $2.39
- Derek J. Maetzold · August 5, 2026 · Sale473 @ $30.68
- Derek J. Maetzold · August 5, 2026 · Sale556 @ $30.68
- Derek J. Maetzold · August 5, 2026 · Sale2.5K @ $30.68
- Derek J. Maetzold · August 4, 2026 · Option Exercise20.4K @ $2.39
- Derek J. Maetzold · August 4, 2026 · Sale4.1K @ $31.34
- Derek J. Maetzold · August 4, 2026 · Sale4.8K @ $31.34
- Derek J. Maetzold · August 4, 2026 · Sale11.9K @ $31.34
- Derek J. Maetzold · August 4, 2026 · Sale2.9K @ $30.79
- Derek J. Maetzold · August 4, 2026 · Sale3.4K @ $30.79
- Derek J. Maetzold · August 4, 2026 · Sale8.4K @ $30.79
Institutional Ownership
March 31, 2026
- Total shares held
- 26.46M
- Total value held
- $626.93M
- Institutional holders
- 179
- Unknown2.98M
- Unknown2.76M
- Unknown1.77M
- Unknown1.35M
- Unknown1.18M
- Unknown1.04M
- Unknown940.7K
- Unknown811.3K
- Unknown769.1K
- Unknown728.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Castle Biosciences Publishes AD Molecular Testing Study, Opens New Lab
Castle Biosciences highlighted a new study that shows a strong need for molecular testing in atopic dermatitis, supporting its AdvanceAD‑Tx product. The company also announced a new laboratory and office facility in Scottsdale, Arizona, expanding its testing capabilities. These developments reinforce the company's focus on precision diagnostics for skin conditions.
Castle Biosciences Publishes AD Molecular Testing Study, Opens New Lab. Castle Biosciences highlighted a new study that shows a strong need for molecular testing in atopic dermatitis, supporting its AdvanceAD‑Tx product. The company also announced a new laboratory and office facility in Scottsdale, Arizona, expanding its testing capabilities. These developments reinforce the company's focus on precision diagnostics for skin conditions.